SSY Group (HKG:2005) said it received Chinese regulatory approvals for drug production and registration for two products, according to a Hong Kong bourse filing Friday.
The approvals cover a combination injection of electrolytes, sodium acetate and glucose to treat dehydration when oral administration is not possible, and a metoclopramide hydrochloride injection to treat vomiting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments